Background/Aims Nonalcoholic steatohepatitis (NASH) is prevalent in both economically developed and developing countries. Twenty percent of NASH progresses to cirrhosis with/without hepatocellular carcinoma, and there is an urgent need to find biomarkers for early diagnosis and monitoring progression of the disease. Using immunohistochemical and immunoelectron microscopic examination we previously reported that expression of matrix metalloproteinase-1 (MMP-1) increased in monocytes, Kupffer cells and hepatic stellate cells in early stage NASH. The present study investigated whether serum MMP-1 levels reflect disease activity and pharmaceutical effects in NASH patients.
Methods We measured the serum levels of MMPs, tissue inhibitors of metalloproteinases (TIMPs), and several cytokines/ chemokines in patients with histologically proven early and advanced stages of NASH and compared them with those in healthy controls.
Results Serum MMP-1 levels in stage 1 fibrosis, but not in the more advanced fibrosis stages, were significantly higher than in healthy controls (P=0.019). There was no correlation between serum MMP-1 level and fibrosis stage. Serum MMP- 1 levels in NASH patients represented disease activity estimated by serum aminotransferase values during the followup period. In contrast, MMP-2, MMP-9 and TIMPs did not change with disease activity. Consistent with the finding that MMP-1 is expressed predominantly in monocytes and Kupffer cells, serum levels of monocyte chemotactic protein-1 and granulocyte-colony stimulating factor were significantly increased in NASH with stage 1 fibrosis.
Conclusions These results suggest that serum MMP-1 levels represent disease activity and may serve as a potential biomarker for monitoring the progression of NASH.
Citations
Citations to this article as recorded by
Research advances in the diagnosis and treatment of MASLD/MASH Dekai Wang, Jinxian Miao, Lihua Zhang, Lin Zhang Annals of Medicine.2025;[Epub] CrossRef
Comparative efficacy of febuxostat and vitamin E in the management of MASLD: Insights from a randomized parallel clinical study Hadier El-Sheikh, Sahar El-Haggar, Rehab Badawi, Eslam Habba European Journal of Pharmacology.2025; 1000: 177735. CrossRef
A Noninvasive Predictors of Significant Histological Activity in Chronic Liver Diseases: The Role of Matrix Metalloproteinases A. V. Yagoda, P. V. Koroy, T. R. Dudov The Russian Archives of Internal Medicine.2025; 15(3): 216. CrossRef
Disruption of small intestinal mucosal homeostasis in mice with amiodarone induced steatohepatitis Shoji Kawauchi, Sayo Horibe, Toru Tanaka, Naoto Sasaki, Junichi Kunimasa, Yoshiyuki Rikitake Scientific Reports.2025;[Epub] CrossRef
Sclareol mitigates steatosis, inflammation, and fibrosis through the regulation of AMPK/SREBP1/NF-κB/TGF-β pathways in metabolic dysfunction-associated steatohepatitis Poonam Yadav, Sumeet Kumar Singh, Ralf Weiskirchen, Umashanker Navik Biomedicine & Pharmacotherapy.2025; 191: 118512. CrossRef
Matrix metalloproteinases and morphological features in chronic liver diseases A. V. Yagoda, P. V. Koroy, T. R. Dudov Experimental and Clinical Gastroenterology.2024; (10): 153. CrossRef
Evaluation of the Diagnostic Utility of Selected Serum Adipokines and Cytokines in Subjects with MASLD—A Pilot Study Beata Zyśk, Lucyna Ostrowska, Joanna Smarkusz-Zarzecka, Karolina Orywal, Barbara Mroczko, Urszula Cwalina Nutrients.2024; 16(9): 1381. CrossRef
3D microscaffolds with triple-marker sensitive nanoprobes for studying fatty liver disease in vitro Simran Kaur Rainu, Neetu Singh Nanoscale.2024; 16(20): 10048. CrossRef
Inflammatory Markers Involved in the Pathogenesis of Dupuytren's Contracture
William T. Cates, Janet M. Denbeigh, Ralph T. Salvagno, Sanjeev Kakar, Andre J. van Wijnen, Charles Eaton Critical Reviews in Eukaryotic Gene Expression.2024; 34(6): 1. CrossRef
Pro-Inflammatory Adipokine and Cytokine Profiles in the Saliva of Obese Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)—A Pilot Study Beata Zyśk, Lucyna Ostrowska, Joanna Smarkusz-Zarzecka, Katarzyna Witczak-Sawczuk, Agnieszka Gornowicz, Anna Bielawska International Journal of Molecular Sciences.2023; 24(3): 2891. CrossRef
Analysis of the Genetic Relationship between Atherosclerosis and Non-Alcoholic Fatty Liver Disease through Biological Interaction Networks Francisco Andújar-Vera, María Ferrer-Millán, Cristina García-Fontana, Beatriz García-Fontana, Sheila González-Salvatierra, Raquel Sanabria-de la Torre, Luis Martínez-Heredia, Blanca Riquelme-Gallego, Manuel Muñoz-Torres International Journal of Molecular Sciences.2023; 24(4): 4124. CrossRef
Low-grade inflammation is associated with a heterogeneous lipoprotein subclass profile in an apparently healthy population sample Daniel L. Pontzen, Martin Bahls, Diana Albrecht, Stephan B. Felix, Marcus Dörr, Till Ittermann, Matthias Nauck, Nele Friedrich Lipids in Health and Disease.2023;[Epub] CrossRef
Extracellular matrix turnover: phytochemicals target and modulate the dual role of matrix metalloproteinases (MMPs) in liver fibrosis Usman Sabir, Hong‐mei Gu, Da‐Wei Zhang Phytotherapy Research.2023; 37(11): 4932. CrossRef
Matrix Metalloproteinase-9 as a Potential Biomarker in 631 Human Implant-Induced Fibrotic Capsules: Analysis and Biomarker Study Britta Kuehlmann, Clark Andrew Bonham, Geoffrey C. Gurtner, Lukas Prantl Plastic & Reconstructive Surgery.2023; 152(4): 637e. CrossRef
Impacts of Non-alcoholic Fatty Liver Disease on Acute Coronary Syndrome: Evidence and Controversies Shun-Yi Shi, Fang Jia, Meng-Fei Wang, Ya-Feng Zhou, Jian-Jun Li Current Atherosclerosis Reports.2023; 25(10): 751. CrossRef
Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease Yuna Kim, Eugene Han, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Mi Kyung Kim, Hye Soon Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Yong-ho Lee, Seung Up Kim Gut and Liver.2022; 16(2): 290. CrossRef
Concentration of Serum Matrix Metalloproteinase-3 in Patients With Primary Biliary Cholangitis Alicja Bauer, Andrzej Habior Frontiers in Immunology.2022;[Epub] CrossRef
Applications of Quantitative Systems Pharmacology (QSP) in Drug Development for NAFLD and NASH and Its Regulatory Application Scott Q. Siler Pharmaceutical Research.2022; 39(8): 1789. CrossRef
Improved anti-fibrotic effects by combined treatments of simvastatin and NS-398 in experimental liver fibrosis models Seong Hee Kang, Hyung Joon Yim, Ji-won Hwang, Mi-jung Kim, Young-Sun Lee, Young Kul Jung, Hyungshin Yim, Baek-Hui Kim, Hae-Chul Park, Yeon Seok Seo, Ji Hoon Kim, Jong Eun Yeon, Soon Ho Um, Kwan Soo Byun The Korean Journal of Internal Medicine.2022; 37(4): 745. CrossRef
The 1G/1G+1G/2G Genotypes ofMMP1rs1799750 Are Associated with Higher Levels of MMP-1 and Are Both Associated with Lipodystrophy in People Living with HIV on Antiretroviral Therapy Andreia Soares da Silva, Maria do Socorro de Mendonça Cavalcanti, Taciana Furtado de Mendonça Belmont, Ricardo Arraes de Alencar Ximenes, Aline Vieira da Silva, Débora Nascimento da Nóbrega, Roberta dos Santos Souza, Isabela Cristina Cordeiro Farias, Kley AIDS Research and Human Retroviruses.2021; 37(5): 399. CrossRef
Identification and Optimization of a Minor Allele-Specific siRNA to Prevent PNPLA3 I148M-Driven Nonalcoholic Fatty Liver Disease Justin K. Murray, Jason Long, Lei Liu, Shivani Singh, Danielle Pruitt, Michael Ollmann, Elissa Swearingen, Miki Hardy, Oliver Homann, Bin Wu, Jerry Ryan Holder, Kelvin Sham, Brad Herberich, Mei-Chu Lo, Hui Dou, Artem Shkumatov, Monica Florio, Ingrid C. Ru Nucleic Acid Therapeutics.2021; 31(5): 324. CrossRef
Non-alcoholic fatty liver disease as an independent factor of cardiometabolic risk of cardiovascular diseases D. V. Garbuzenko, D. V. Belov Experimental and Clinical Gastroenterology.2021; (10): 22. CrossRef
Cellular protein markers, therapeutics, and drug delivery strategies in the treatment of diabetes-associated liver fibrosis Chien-Yu Lin, Pratik Adhikary, Kun Cheng Advanced Drug Delivery Reviews.2021; 174: 127. CrossRef
Matrix metalloproteinase-1 decorated polymersomes, a surface-active extracellular matrix therapeutic, potentiates collagen degradation and attenuates early liver fibrosis Eline Geervliet, Silvia Moreno, Luca Baiamonte, Richell Booijink, Susanne Boye, Peng Wang, Brigitte Voit, Albena Lederer, Dietmar Appelhans, Ruchi Bansal Journal of Controlled Release.2021; 332: 594. CrossRef
Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors Sophie C. Cazanave, Andrew D. Warren, Maciej Pacula, Fayçal Touti, Anna Zagorska, Nil Gural, Eric K. Huang, Sarah Sherman, Mehar Cheema, Sabrina Ibarra, Jamie Bates, Andrew N. Billin, John T. Liles, Grant R. Budas, David G. Breckenridge, Dina Tiniakos, Vl Science Translational Medicine.2021;[Epub] CrossRef
Matrix metalloproteinase-1 as a non-invasive biomarker to assess liver fibrosis in children with chronic liver disease Ola Galal Behairy, Mohamed Mostafa El-Bakry, Amira Ibrahim Mansour, Amira M. N. Abdelrahman, Ghada Mansour Emam Egyptian Liver Journal.2021;[Epub] CrossRef
Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease Raffaele Galiero, Alfredo Caturano, Erica Vetrano, Arturo Cesaro, Luca Rinaldi, Teresa Salvatore, Raffaele Marfella, Celestino Sardu, Elisabetta Moscarella, Felice Gragnano, Paolo Calabrò, Ferdinando Carlo Sasso Reviews in Cardiovascular Medicine.2021;[Epub] CrossRef
Matrix Metalloproteinases as Potential Biomarkers and Therapeutic Targets in Liver Diseases Eline Geervliet, Ruchi Bansal Cells.2020; 9(5): 1212. CrossRef
Sequential Matrix Metalloproteinase-1 Expression Triggered by Infiltrating Monocytic Lineage Cells Modulates Pathophysiological Aspects of Human Nonalcoholic Steatohepatitis
Ratio of Serum Aspartate to Alanine Aminotransferase as a Marker of Isolated Coronary Artery Ectasia and its Severity Danesh Soltani, Samira Jafari, Haleh Ashraf, Amir Sobh-Rakhshankhah, Zahra Kolahchi, Farzad Masoudkabir, Mohammad Ali Boroumand, Ali Vasheghani-Farahani Heart International.2020; 14(1): 43. CrossRef
Relationship between non-alcoholic fatty liver disease and coronary heart disease Ugur Arslan, Mustafa Yenerçağ World Journal of Clinical Cases.2020; 8(20): 4688. CrossRef
Recent Insight into the Role of Fibrosis in Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma Antonio Sircana, Elena Paschetta, Francesca Saba, Federica Molinaro, Giovanni Musso International Journal of Molecular Sciences.2019; 20(7): 1745. CrossRef
A Bioreactor Technology for Modeling Fibrosis in Human and Rodent Precision‐Cut Liver Slices Hannah L. Paish, Lee H. Reed, Helen Brown, Mark C. Bryan, Olivier Govaere, Jack Leslie, Ben S. Barksby, Marina Garcia Macia, Abigail Watson, Xin Xu, Marco Y.W. Zaki, Laura Greaves, Julia Whitehall, Jeremy French, Steven A. White, Derek M. Manas, Stuart M. Hepatology.2019; 70(4): 1377. CrossRef
Novel breast cancer screening: combined expression of miR-21 and MMP-1 in urinary exosomes detects 95% of breast cancer without metastasis Wataru Ando, Kiyoshi Kikuchi, Takayuki Uematsu, Hiroaki Yokomori, Takashi Takaki, Masaya Sogabe, Yutaka Kohgo, Katsuya Otori, Shigemi Ishikawa, Isao Okazaki Scientific Reports.2019;[Epub] CrossRef
Recent advances in the non-invasive assessment of fibrosis using biomarkers Amanda L Tatler Current Opinion in Pharmacology.2019; 49: 110. CrossRef
First
Prev
